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Abstract
Tuberculosis, caused by Mycobacterium tuberculosis (Mtb), is a leading cause of death in 
humans worldwide. The emergence of antibiotic-resistant strains of Mtb is a threat to 
tuberculosis control. A general belief is that drug resistance is acquired by Mtb during 
antibiotic treatment by accumulation of spontaneous mutations. Also, it is known that 
the drug resistance mutations (DRM) have an associated fitness cost, reducing the trans-
missibility and virulence of resistant strains. In this work we show that many canonical 
DRM are clade specific; i.e. they occur only in specific genetic lineages of Mtb and depend 
on a specific genetic context necessary for the reduction of the fitness cost and sustainabil-
ity of the drug resistance phenotype. Dependence of the drug resistance on occurrence of 
genetic variants of multiple genes and specific activities of the encoded proteins allows 
combating the drug resistance by impairing the global genetic context. A new drug, FS-1, 
reverses antibiotic resistance by compromising this genetic context and aggravating the 
fitness cost of DRM.
Keywords: antibiotic resistance, drug resistance mutation, genomic polymorphism, 
drug resistance reversion
1. Introduction
Tuberculosis (TB), the infectious disease caused by Mycobacterium tuberculosis (Mtb), is the 
leading cause of death from a single infectious disease in humans worldwide. Roughly 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
one-third of the world’s population has latent TB, providing a source of infection. Efforts 
to curb TB have resulted in 2% annual decline in the global incidence of TB, except in sub-
Saharan Africa [1]. However, the emergence of antibiotic-resistant strains of Mtb is a threat 
to TB control. If antibiotic-resistant TB is not rapidly and appropriately diagnosed, it may 
lead to an increase in mortality rates and the spread of resistant strains in the population.
The first line antibiotics rifampicin (RIF) and isoniazid (INH), were developed against Mtb 
in the 1950s and 1960s, and are still the most effective treatments for TB. An estimated 20% 
of all Mtb isolates are resistant to at least one of the major antibiotics [2]. Multidrug-resistant 
tuberculosis (MDR-TB) is defined as TB that does not respond to at least rifampicin (RIF) and 
isoniazid (INH), while extensively drug-resistant TB (XDR-TB) is defined as TB resistant to 
INH and RIF in addition to resistance to any of the fluoroquinolones (FLQ) and to at least one 
of the three second-line injectable drugs: amikacin (AMK), capreomycin (CAP) or kanamycin 
(KAN). Antibiotic resistance arises when bacteria acquire mutations in drug target genes in 
an infected patient receiving antibiotics, usually as a result of mismanagement of treatment. 
Primary resistance arises when resistant strains are transmitted from one patient to another.
Efforts to control drug-resistant TB have relied on two beliefs: that most drug resistance is 
acquired de novo during Mtb treatment regiments, i.e., secondary resistance, and that drug-resis-
tance mutations would have an associated fitness cost reducing the transmissibility and viru-
lence of resistant strains [2]. Therefore, TB control has focused on increasing the effectiveness of 
the first line treatment and of drug-susceptibility tests only in patients who have received anti-
TB medication previously. An added challenge is that diagnosing MDR- and XDR-TB requires 
drug-susceptibility testing with six different drugs, which can take several weeks to months [3].
Results from improved molecular diagnostic methods have challenged these two beliefs. 
First, an increase in the prevalence of MDR- and XDR-TB appeared to be driving the spread 
of TB in some areas. For example, primary transmission of MDR- and XDR-TB is the main 
driving force of drug-resistant TB spread in sub-Saharan Africa [2]. Second, drug-resistance 
mutations have variable effects on fitness and transmissibility. Mutations associated with 
resistance to INH, RIF, and streptomycin (SM) have even been associated with low or no 
fitness costs [4]. Secondary mutations that compensate for drug resistance mutations appear 
rapidly after the emergence of drug resistance, in the same gene or in genes involved in linked 
metabolic pathways, and act to restore virulence and may even increase transmissibility [2].
The WHO recommends the Xpert MTB/RIF assay for the diagnosis of rifampicin resistance, 
and molecular line probe assays for the detection of resistance to first and second line drugs. 
Many countries with a high TB burden now implement the Xpert MTB/RIF assay, which can 
be used as a marker for MDR-TB, as INH resistance generally precedes RIF resistance [5]. 
Microbiological culture is still the reference standard for diagnosis of TB and of drug-resis-
tance. TB remains very difficult to manage in resource-poor areas. Whole-genome sequencing 
(WGS) and detection of variants holds great promise for characterizing all of the resistance 
markers (as opposed to a limited range of mutations) as well as genotyping the strain of Mtb, 
but relies on a more complete understanding of the relationship between genotype, specific 
drug resistance mutations, activity states of multiple genes and encoded proteins, and the 
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drug-resistance phenotype [6]. A new promising drug, FS-1, consisting of a nano-molecular 
complex of iodine atoms ligated to a dextrin-polypeptide network, was reported to cause 
antibiotic resistance reversion in MDR-TB by compromising the genetic context of the drug 
resistance phenotype and by aggravating the fitness cost of the drug resistance mutations [7].
2. Genetic mechanisms of drug resistance in Mtb
The major antibiotics for the treatment of TB have four different mechanisms of action: (i) 
inhibition of RNA synthesis; (ii) inhibition of protein synthesis; (iii) inhibition of cell wall 
biosynthesis; and (iv) by interfering with the synthesis of cell membranes [8].
Since the early 1990s, numerous studies have described the genetic mechanisms of drug resis-
tance in Mtb, and there is a quantity of data on the polymorphisms found in isolates resis-
tant to specific antibiotics. Mtb is highly clonal, and as such there is little or no horizontal 
gene transfer, implying that antibiotic resistance is due to point mutations or deletions. Drug-
resistance mutations occur in genes coding for the antibiotic target itself (e.g., gyrA, gyrB, rrs), 
in genes that code for enzymes needed for activating the antibiotic (e.g., katG, inhA, rpoB, pncA, 
embB), or in promoter regions of these genes [2, 9]. To date, there are 1031 mutations in the 
Mtb genome believed to be associated with resistance to nine major groups of antibiotics, with 
different combinations of mutations causing MDR-TB [10]. Many of the mutations identified 
are thought to play roles other than causing resistance directly, e.g., compensatory or adaptive 
roles, to increase fitness, which is being reduced by the drug-resistance mutations [8].
Researchers have not fully elucidated the mechanisms by which drug resistance emerges and 
is preserved in Mtb populations [11]. Early mathematical models of MDR-TB suggested that 
DR mutations would impose fitness costs that would tend to select against the mutation in the 
population and thus limit the spread of TB [12]. However, current research has shown that DR 
mutations have a variable effect on fitness and transmissibility. INH, RIF and SM resistance 
have even been associated with low or no fitness costs [2, 4].
Table 1 summarizes the literature data [7, 13–15] on the roles of the major antibiotics used to 
treat TB and known genes involved in drug-resistance, as well as the mechanisms thought to 
be responsible for drug-resistance. Drug resistant phenotype in Mtb is associated exclusively 
with mutations at specific positions in bacterial genomes. No events of a horizontal acquisi-
tion of drug resistance genetic determinants were reported for Mtb. Mutations in protein 
coding genes either alter drug target molecules or reduce activity of enzymes converting pro-
drug molecules into active antibiotics, e.g., katG gene, which encodes a catalase converting 
isoniazid to an active isonicotinoyl-NAD adduct [16]. Mutations affecting activities of bacte-
rial enzymes usually reduce viability of bacteria. This phenomenon is known as the fitness 
cost of drug resistance. Overcoming of the fitness cost requires from bacteria an acquisition 
of secondary mutations to compensate the side effects of DR mutations. We hypothesized in 
this paper that the necessity for bacteria to compensate the side effects of DR mutations poten-
tially opens new ways to identify molecular targets for new drugs to induce the reversion of 
antibiotic resistance in bacterial populations.
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Antibiotic name Mechanism of action Some polymorphisms in 
Mtb causing resistance
Mechanism of drug 
resistance
First line 
drugs
Rifampicin, RIF Inhibits bacterial RNA 
polymerase by binding 
it. When RIF binds 
to the RpoB target, 
hydroxyl radicals are 
formed and this has a 
cytotoxic effect.
Most mutations occur in 
cluster I of rpoB(β subunit 
of RNA pol), in the 81 bp 
rifampicin resistance 
determining region (RRDR)
Drug target is altered.
In resistant bacteria, 
hydroxyl radicals are 
not formed when RIF 
binds to RpoB, so cells 
do not die.
Ethambutol, EMB Affects several cellular 
pathways, mostly 
arabinogalactan 
biosynthesis 
through inhibition 
of cell wall arabinan 
polymerization; RNA 
metabolism, transfer 
of mycolic acid into 
cell wall, phospholipid 
synthesis, spermidine 
synthesis
Point mutations in the 
embCAB operon or the emb 
genes, affecting expression 
of the embA, embB, and 
embC genes
Alteration of the drug 
target
Isoniazid, INH INH is a pro-drug, 
activated by the 
catalase-peroxidase 
enzyme KatG and then 
binds to InhA. Disrupts 
multiple pathways, 
mainly interferes with 
synthesis of mycolic 
acid.
Mutations to katG gene 
(50–80%): Mostly S315 T.
Mutations to inhA, or the 
promoter region
Mutations in ndh gene 
(NADH dehydogenase), 
kasA and ahpC genes
Mutations in kasA gene
katG: mutations 
decrease catalase and 
peroxidase activity, 
so reduce activation 
of INH
inhA promoter: 
overexpression of the 
enzyme
Pyrazinamide, PZA Activated by enzyme 
pyrazinamidase 
(PZase). Mechanism 
poorly understood. 
Disruption of the 
proton motive force 
required for essential 
membrane transport 
functions by POA at 
acidic pH.
Mutations in the pncA gene 
encoding PZase, most are 
in 561-bp region of the 
open reading frame or 
in an 82-bp region of its 
promoter.
Pro-drug cannot be 
converted to its active 
form
Aminoglycosides: 
streptomycin, SM
Binds to the small 
16S rRNA of the 30S 
subunit of bacterial 
ribosome, interfering 
with the binding 
of tRNA to the 30S 
subunit
Mutation of the ribosome 
target binding sites:
50% in the rpsL gene, which 
encodes the ribosomal 
protein S12, usually K43R
20% mutations to the rrs 
gene.
Also mutations in gidB, 
which encodes 16S rRNA 
methyltransferase
Alteration of the drug 
target
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Antibiotic name Mechanism of action Some polymorphisms in 
Mtb causing resistance
Mechanism of drug 
resistance
Second 
line 
drugs
Aminoglycosides: 
kanamycin KAN, 
amikacin AMK
Binds to the small 
16S rRNA of the 30S 
subunit of bacterial 
ribosome, interfering 
with the binding 
of tRNA to the 30S 
subunit
Mutation of the ribosome 
target binding sites genes 
rrs, but not cross-resistant 
with streptomycin
Alteration of drug 
target
Capreomycin, CAP Inhibits protein 
synthesis through 
modification of 
ribosomal structures at 
the 16S rRNA
Mutations in the rrs gene 
encoding 16S rRNA
mutations in the 
gene tlyA encoding a 
2’-O-methyltransferase of 
16S rRNA and 23S rRNA
Alteration of drug 
target
Ethionamide, ETH ETH requires activation 
by monooxygenase 
EthA, inhibits mycolic 
acid synthesis by 
binding the ACP 
reductase InhA
70% due to mutations in 
ethA or inhA
Similar to INH:
inhA promoter: 
overexpression of the 
enzyme
Fluoroquinolones (FLQ), 
e.g., ofloxacin (OFX), 
moxifloxacin (MOX)
Trapping gyrase 
on DNA as ternary 
complexes, thereby 
blocking the movement 
of replication forks 
and transcription 
complexes
Usually multiple mutations 
in conserved quinolone 
resistance-determining 
region (QRDR) of gyrA 
and gyrB, most often at 
positions Ala-90 and Asp-
94 in gyrA
[Mutations at position 
80 of gyrA cause 
hypersusceptibility to 
fluoroquinolones]
FLQ traps the DNA-
gyrase complex in 
which the DNA is 
broken. Resistant GyrA 
prevents chromosome 
breakage.
Para-aminosalicylic acid, 
PAS
PAS is a prod-drug and 
thymidylate synthase 
A is required for 
conversion to active 
form
PAS inhibits folic 
acid biosynthesis and 
uptake of iron
Mutations in the thyA 
gene encoding the enzyme 
thymidylate synthesis of 
the folate biosynthesis 
pathway, mostly Thr202Ala
Also: mutations in folC, 
ribD, dfrA
Pro-drug cannot be 
converted to active 
drug
Cycloserine, CS Interrupts 
peptidoglycan 
synthesis (for cell 
wall) by inhibiting the 
enzymes d-alanine 
racemase (AlrA) and 
d-alanine:d-alanine 
ligase (Ddl)
To be determined
alr, ddl, cycA
Unknown
Table 1. The main anti-TB drugs, mechanisms of actions and resistance-conferring polymorphisms.
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3. Drug-resistance against the background of Mtb genetic clades and 
current diagnostic approaches
The disease TB first appeared roughly 70,000 years ago [17]. Studies show that Mtb arose as 
an obligate human pathogen and that different strains co-evolved with humans, migrated 
out of Africa, and that the populations expanded with their human hosts [18]. The migrations 
of modern humans out of Africa and the increased population density during the Neolithic 
period could be at the origin of its expansion. This theory is consistent with the bacterium’s 
phylogeny and phylogeography [19].
Genetic analyses of global strains have revealed that distinct lineages of Mtb have emerged 
in different regions of the world. The considerable genetic diversity between these lineages 
is linked to ancient human migrations out of Africa and to more recent movements and pop-
ulation growth [20]. Hershberg et al. demonstrate that there is a greatly reduced selection 
pressure in Mtb, owing to factors including high clonality of Mtb and serial transmission bot-
tlenecks, both of which reduce the effective population size, increasing the effects of genetic 
drift [20]. Mutations can reach high functional diversity without being eliminated, which has 
implications for the emergence of MDR-TB.
During diagnostic procedures, it is helpful to find the lineage of the infecting Mtb strain(s), 
because some lineages might have acquired specific virulence and/or resistance features before 
expanding [21]. Clades differ by growth rate and in patterns of host-pathogen interaction in 
terms of cytokine induction and rate of uptake by macrophages [22]. Lineage 2 (Beijing clade) 
also is associated with hyper-virulence and with an extended drug resistance pattern [23].
Here we discuss research papers investigating the feasibility of replacing phenotypic drug 
testing of Mtb with molecular diagnostic techniques. All of them rely on understanding the 
genetic mechanisms underlying the development and persistence of drug-resistance in Mtb 
strains, including the context of lineages with varying evolutionary histories.
Köser et al. were among the first to publish a method for rapid WGS analysis of an Mtb clini-
cal specimen to reduce the time of XDR-TB diagnosis. They used SNPs to identify lineages, 
combined with a catalog of well-described DR polymorphisms, demonstrating that WGS is 
superior to current genotypic tests, but not yet as reliable as phenotypic testing [24].
Rodwell et al. of the Global Consortium for Drug-Resistant TB Diagnostics (GCDD) investigated 
whether a certain collection of mutations can be used as markers of drug resistance in a molecu-
lar diagnostic test. They studied a collection of MDR and XDR-TB strains from different regions. 
Their approach was to select eight genes (katG, inhA, rpoB, gyrA, gyrB, rrs, eis, and thyA) in which 
mutations are known to be strongly associated with resistance to the antibiotics INH, RIF, FLQ, 
AMK, KAN, and CAP. In each specimen, the eight genes were amplified and sequenced, and 
variants were detected against the H37Rv reference strain. The specificity and sensitivity of the 
identified variants for drug resistance were determined. They concluded that about 30 mutations 
in six genes predicted XDR-TB phenotypes with 90–98% sensitivity and almost 100% specificity 
[3]. However, using these 30 mutations diagnostically would rely on purifying mycobacterial 
DNA from clinical samples and amplifying the genes of interest before identifying the presence 
of the mutations. Such a test would rely on broad sequencing coverage and accurate base calling 
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for the mutations of interest. The study used samples from four geographic regions, but the 
results do not specify the lineages of the resistant strains. This is problematic, because some DR 
mutations are lineage specific. More details on the mechanisms of drug resistance summarized 
from literature sources are in Table 1. It should also be noted that the mutations in the identified 
target genes do not explain all cases of drug resistance.
Genome-wide association studies (GWAS) exploit the rapid turnover and high throughput of 
NGS, identifying variants in natural populations linked to phenotypic traits by statistical associ-
ation. Bacterial GWAS have not been frequently used because their population structures reduce 
the power of association or produce false positives [25]. The clonal nature of bacterial reproduc-
tion—especially prevalent in Mtb—means that spurious variations can be strongly associated 
with particular phenotypes [26]. However, Earle et al. have successfully used a linear mixed 
model approach to perform GWAS on four species of bacteria, including Mtb, to show associa-
tions between genetic variation and antibiotic resistant phenotypes. The success of this approach 
depended on “controlling population structure and boosting power by recovering signals of 
lineage-level associations” [27]. This method allows the researcher to eliminate signals due only 
to population, while preserving strain-specific signals that contribute to the DR phenotype.
Coll et al. identified a proposed minimum set of SNPs that can be used to differentiate all 
seven Mtb lineages and 55 sublineages [28]. They identified 88 SNPs in DR candidate regions 
(two promoters, 21 genes). However, this list of SNPs is aimed at identifying lineages, and is 
not necessarily informative about drug-resistance in the strains.
Feuerriegel et al. showed that many polymorphisms in Mtb previously known to be associ-
ated with DR are useful for distinguishing clades, which indicates a lineage specificity of 
drug resistance [29]. The same team designed the first available web-based drug resistance 
analysis tool, the Phylo-Resistance Search Engine (PhyResSE) [30]. The tool was evaluated 
by testing 92 Mtb strains from Sierra Leone with known drug resistance phenotypes, either 
mono-resistant (RIF, INH or SM) or poly-resistant (RIF, INH, SM, ethambutol (EMB) or pyra-
zinamide (PZA)). The major advantage of this tool is that it forms a complete analysis pipe-
line, taking FASTQ files as input: including quality control, mapping and base recalibration 
prior to genotyping. Thus the end-user need not do complex bioinformatic analysis. This 
requires considerable computational power. PhyResSE uses a variant catalog based on vali-
dated resistance-SNPs from literature as well as from their own experimental data for phy-
logenetic and drug resistance diagnosis, including lineage-specific resistance mutations. The 
paper does not give detailed descriptions of the methods used for inclusion or exclusion of 
specific mutations, or how the sensitivity and specificity were calibrated for mutations, as 
some mutations may confer only low-level resistance. The program returns a plain-language 
output which cites the experimental support for the result and also states whether or not there 
is a high degree of confidence in a particular polymorphism conferring drug resistance. The 
strains used to evaluate the tool in the paper do not include MDR or XDR strains. Excessive 
contamination and/or poor sequencing coverage would provide a barrier to correct diagnosis.
One of the few studies using gene pairs associated with drug resistance was by Cui et al. [31]. 
The rationale for the study was that evolution of transmissible drug-resistant Mtb is caused by 
multiple mutations, many of which interact with each other. This study used nearly 300 Mtb 
genome sequences from public datasets and their phenotypic drug-sensitivity testing results. 
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The variants were identified using a standard variant-calling approach. The resulting vari-
ants were first filtered using PLINK to remove phylogenetically related variants. The remain-
ing mutations were analyzed using the program GBOOST, which performs a Chi-square test 
to confirm associations between two variants and phenotype. The resulting gene pairs were 
screened for the presence of drug target genes and further filtered by non-synonymous muta-
tions. The resulting gene pairs were: one for INH, one for RIF, four for EMB and five for ethi-
onamide (ETH). The authors reported that most of the identified gene pairs containing drug 
targets consisted of the unique mycobacterial Pro-Pro-Glu (PPE) family proteins, and from 
this they infer that PPE family proteins play an important role in Mtb drug resistance [30]. The 
identified mutations were not validated in this study, but the study does show the potential 
for using pairs of mutations in the diagnosis of drug resistance rather than single mutations. 
It should be noted that the PPE family proteins make up 10% of the Mtb genome, and they are 
highly polymorphic, so associations with these genes might occur as a result of genetic drift 
rather than selection pressure [32]. The value of removing population-specific mutations is 
unclear, as some lineages of Mtb are strongly associated with drug resistance.
Mortimer et al. proposed a method of distinguishing DR loci under positive selection [33]. The 
rationale behind this is that methods for identifying advantageous mutations usually depend 
on recombination to differentiate target loci from neutral variants, which is not feasible in the 
case of Mtb. They analyzed over 1000 Mtb genomes from Russia and South Africa, mostly 
Lineages 2 (Beijing) and 4, and examined the frequency of different mutations in the popula-
tions. They found that resistant sub-populations are less diverse than susceptible subpopula-
tions, which is consistent with the ongoing transmission of resistant Mtb. They classified the 
DR mutations as either “tight targets” or “sloppy targets” based on their diversity. The authors 
also noted that lipid metabolism genes are enriched in the list of DR loci under positive selec-
tion. This approach has potential for understanding the genetics of resistance in clonal bacteria.
A variety of bioinformatic approaches have been useful for resolving the evolution of the various 
lineages of Mtb over time, for tracing the emergence of pathogenic and more virulent strains, and 
for identifying variants in Mtb genomes responsible for the development of antibiotic resistance 
[28, 34–36]. In tandem with methods for rapid identification of drug resistance, researchers are 
also investigating methods of exploiting our understanding of the evolution of drug resistance. 
Treatment of TB with antibiotics has had an overall effect of selecting for drug resistance, rather 
than having the hoped-for effect of selecting DR variants with reduced fitness. Baym et al. have 
reviewed possible mechanisms of selection for drug resistance inversion [37]. These rely on the con-
cept of using combinations of antibiotics and other compounds to inhibit bacterial growth and at 
the same time reversing the selection for resistance, similar to the combination of penicillin and cla-
vulanic acid to block bacterial β-lactamase, while minimizing or reversing selection for resistance. 
This avenue shows promise, particularly in combination with quick genotyping of clinical samples.
4. Non-random associations between polymorphic sites in genomes 
of M. tuberculosis
Data for this research was sourced from the GMTV database [17], which consists of SNPs 
and indels for a large number of Mtb strains for which whole genome sequencing was 
Basic Biology and Applications of Actinobacteria86
performed. Also, this database integrates clinical, epidemiological and microbiological 
data for all the recorded Mtb isolates. Analysis of this study compared distribution pat-
terns of 58,025 amino acid substitutions in 1089 Mtb strains from the GMTV database. The 
polymorphisms were determined relative to the H37Rv reference strain [38]. Frequencies 
of all polymorphisms were calculated for the entire set of 1089 Mtb genomes and for Mtb 
lineages as they were identified in the GMTV database. Analysis of the data showed that 
many DR polymorphisms were strongly associated with specific Mtb lineages. A mosaic 
plot of the data is shown in Figure 1. Genomes of the Beijing, Haarlem and Lineage 4.3 
clades contained numerous DR mutations, while only a few of them were observed in the 
Lineage 4.1, Ural and X-type. Bacteria of the latter clades appeared to be mostly drug-
susceptible. Statistically significant prevalence of DR mutations in bacteria of specific 
Mtb clades was confirmed by Fisher’s exact test with Bonferroni adjustment. Of these, 25 
DR-polymorphism/lineage pairs showed an odds ratio above 1.
Co-occurrence of alleles of different polymorphic sites was identified by calculating the link-
age disequilibrium (LD) and χ2-statistics. In total, 288,840 pairs of polymorphisms showing 
statistically reliable associations (χ2 above 6.63 corresponds to a p-value ≤ 0.01) were identi-
fied between 823 polymorphic sites including 10 DR mutations [10].Functional associations 
between DR mutations (denoted as mutations from an initial A allele to allele a conferring DR) 
and other genetic polymorphisms (denoted as B for the most frequent allele and b for all other 
alternative variants in Mtb population) were identified by Levin’s attributable risk statistic 
[39]. Confidence range values of attributable risks were calculated by Eq. (1).
  [1 − EXP (ln  (1 −  R a ) − 1.96 × StdErr) ] to  [1 − EXP (ln  (1 −  R a ) + 1.96 × StdErr) ] (1)
In the case of estimation of the risk of DR mutation from A to a in a subpopulation of organ-
isms having the allele b at the secondary polymorphic site, the parameter R
a
 was calculated by 
Eq. (2) and the Fleiss’ standard error parameter StdErr was calculated by Eq. (3).
  R 
a
  =   P AB   P ab −  P aB   P Ab   ______________  
 ( P 
AB
 +  P 
aB
 ) ( P 
aB
 +  P 
ab
 ) 
(2)
  StdErr =  √ _____________   P Ab +  R a ( P AB +  P ab ) ____________N ×  P aB  (3)
Risks of secondary mutations B to b in a DR subpopulation with the genotype a were calcu-
lated by Eq. (1), but in this case the parameters R
a
 and StdErr were calculated by Eqs. (4) and 
(5), respectively:
  R 
a
  =   P AB   P ab −  P aB   P Ab   ______________  
 ( P 
AB
 +  P 
Ab
 ) ( P 
Ab
 +  P 
ab
 ) 
(4)
  StdErr =  √ ____________   P aB +  R a ( P AB +  P ab ) ____________N ×  P Ab  (5)
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In Eqs. (2)–(5), values P
AB
, P
Ab
, P
aB
 and P
ab
 are the frequencies of corresponding allele combina-
tions; and N is the total number of the analyzed Mtb strains = 1089.
The reasoning behind the further analysis is displayed in Figure 2, where two contingency 
tables of co-distribution of an arginine to leucine replacement at position 463 in the protein 
KatG rendering INH resistance [40] and two other secondary mutations are shown. Both pairs 
of mutations are characterized by strong linkage disequilibrium above 0.9. First, the co-distri-
bution of the DR mutation KatG R463L and a polymorphism D69Y in a drug efflux protein Stp 
(Rv2333c) is considered (Figure 2-1). The replacement of the aspartate residue by tyrosine at 
position 69 of the protein Stp is rather common in the Mtb population and it has not been asso-
ciated with any DR phenotype. However, this study showed that 91–99% of the DR mutation 
KatG R463L depends on the presence of the Stp D69Y substitution. In contrast, the likelihood 
of a D → Y replacement in the protein Stp does not depend significantly on the state of the 
KatG R463L polymorphism. The estimated attributable risk is in the range of 21–27%. The con-
fidence ranges of attributable risks in Figure 2 are denoted as A → a
|b
 and B → b
|a
, respectively.
Let us consider another co-distribution of the same DR-related polymorphism KatG R463L 
and a leucine to serine substitution at position 896 in PPE35 protein (Rv1918c), which is 
shown in Figure 2-2. These two mutations are strongly associated with each other, but this 
Figure 1. Mosaic plot representing the contingency table for the presence (black) or absence (gray) of each DR 
polymorphism for each of the 10 loci and the clade for the specimens in the GMTV dataset. The size of the rectangle 
represents the number of sequences in the category. A dotted line indicates that there were no specimens in that category. 
Clades with 10 or fewer representatives were omitted.
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Figure 2. Contingency tables of co-distribution of a DR mutation KatG R463L rendering resistance to INH and two 
secondary polymorphisms in the (1) efflux drug protein Stp and (2) PPE35 protein. Attributable risks of mutation 
acquisition were calculated and denoted as A → a
|b
 and B → b
|a
 for the likelihood of DR mutation acquisition when the 
secondary site is mutated and the likelihood of secondary mutation in a DR sub-population, respectively.
Secondary 
mutations
Drug resistance mutations Annotation
GyrA 
S95 T 
(FLQ)
KatG 
S315 T,N 
(INH)
KatG 
R463L 
(INH)
AccD6 
D229G 
(INH)
ThyA 
T202A 
(PAS)
EmbC 
V981 L 
(EMB)
RpsL 
K43R 
(SM)
GidB 
E92D 
(SM)
GidB 
L16R 
(SM)
Rv0193c 
K417*,E
86.4 to 
94.6
87.5 to 
97.7
77.4 to 
93.1
71.9 to 
90.9
80.7 to 
99.6
78.1 
to 
98.5
79.6 
to 
99.5
81.1 to 
96.0
Hypothetical 
protein
Rv1186c 
P207A,T
84.0 to 
93.9
82.8 to 
96.4
79.8 to 
95.7
76.5 to 
95.0
64.6 to 
94.7
68.7 
to 
96.6
71.8 
to 
98.1
74.4 to 
93.9
Hypothetical 
protein
Rv1321 
S144R
81.8 to 
91.1
84.7 to 
96.0
80.6 to 
94.5
72.5 to 
90.6
67.1 to 
92.9
76.7 
to 
97.4
75.6 
to 
97.3
76.0 to 
92.7
Hypothetical 
protein
Rv2017 
A262E
76.5 to 
86.5
83.9 to 
95.1
73.5 to 
89.4
70.6 to 
88.6
72.9 to 
95.0
75.7 
to 
96.4
77.8 
to 
97.5
76.6 to 
92.4
Transcriptional 
regulator
GalU 
Q235R
76.6 to 
86.6
81.8 to 
93.8
74.9 to 
90.3
69.4 to 
87.8
70.2 to 
93.6
72.9 
to 
95.0
78.0 
to 
97.6
75.3 to 
91.6
UTP-glucose-
1-phosphate 
uridylyltransferase
Rv3204 
T34A
74.7 to 
84.8
82.5 to 
94.1
72.2 to 
88.3
69.1 to 
87.3
68.5 to 
92.4
79.6 
to 
97.8
75.7 
to 
96.4
74.8 to 
91.0
DNA-
methyltransferase
CorA 
K139*,E
76.2 to 
86.1
85.4 to 
95.9
70.7 to 
87.3
67.3 to 
86.1
68.0 to 
92.2
73.5 
to 
95.1
75.4 
to 
96.3
75.9 to 
91.8
Magnesium and 
cobalt transporter
VapC47 
S46 L
74.1 to 
84.4
84.5 to 
95.3
71.0 to 
87.5
71.8 to 
89.1
71.2 to 
93.8
73.8 
to 
95.2
75.7 
to 
96.4
69.3 to 
87.4
VapC47 toxin
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dependence is highly symmetric: in more than 90% of cases both mutations co-occur in the 
same genomes. It may indicate a genetic drift event when the DR phenotype is characteristic 
for a sub-lineage of isolates sharing common ancestry and the neutral mutation in the hyper-
mutable PPE35 protein is a genetic marker of the sublineage.
For further analysis, only those secondary polymorphisms which influenced the DR mutations 
significantly, but were independent, were selected; i.e. cases were selected when confidence 
Secondary 
mutations
Drug resistance mutations Annotation
GyrA 
S95 T 
(FLQ)
KatG 
S315 T,N 
(INH)
KatG 
R463L 
(INH)
AccD6 
D229G 
(INH)
ThyA 
T202A 
(PAS)
EmbC 
V981 L 
(EMB)
RpsL 
K43R 
(SM)
GidB 
E92D 
(SM)
GidB 
L16R 
(SM)
EccC3 
P214R
77.6 to 
87.4
79.7 to 
92.5
71.2 to 
87.8
65.1 to 
84.8
70.2 to 
93.6
72.9 
to 
95.0
74.8 
to 
96.2
66.8 to 
85.9
Type VII secretion 
protein
Rv2542 
T211A
71.8 to 
82.4
81.3 to 
93.4
66.4 to 
84.1
64.9 to 
84.4
71.1 to 
93.8
73.8 
to 
95.2
75.6 
to 
96.4
70.6 to 
88.3
Hypothetical 
protein
PstA1 M5T 87.2 to 
95.3
74.6 to 
90.6
82.9 to 
96.4
84.1 to 
97.6
79.8 to 
99.5
78.8 
to 
99.5
82.3 to 
96.8
Phosphate-transport 
integral membrane 
ABC transporter
TsnR 
L232P
88.6 to 
96.2
72.4 to 
89.0
79.9 to 
94.7
76.6 to 
93.8
80.1 to 
99.5
80.6 to 
95.9
23S rRNA 
methyl-transferase
AroG 
D265E
81.7 to 
92.8
81.5 to 
93.4
77.3 to 
91.6
73.3 to 
93.5
68.5 
to 
90.8
79.5 
to 
96.9
83.4 to 
95.3
Phenylalanine-
repressible DAHP 
synthetase
ProX L85P 61.4 to 
75.4
81.2 to 
92.1
80.0 to 
92.1
76.2 to 
94.2
84.9 to 
95.1
Osmoprotectant
UspA 
V127 L
59.2 to 
74.3
82.1 to 
93.2
78.2 to 
91.3
83.3 to 
98.1
82.5 to 
94.0
Sugar ABC 
transporter
Stp D69Y 53.8 to 
71.1
90.9 to 
98.6
90.7 to 
99.0
83.1 to 
98.9
88.2 to 
97.8
Drug efflux protein
AceAa 
G179D
53.2 to 
70.8
90.8 to 
98.6
87.9 to 
97.8
82.9 to 
98.8
89.4 to 
98.4
Isocitratelyase
GalTb 
T174A
54.0 to 
71.1
84.6 to 
95.3
87.1 to 
97.3
85.3 to 
99.7
89.7 to 
98.5
Galactose-1-
phosphate 
uridylyl-transferase
Rv0324 
T168A
54.8 to 
72.3
87.2 to 
96.9
90.5 to 
98.9
82.6 to 
98.8
89.2 to 
98.4
Transcriptional 
regulator
EspK 
C729S
54.0 to 
70.5
83.6 to 
94.4
85.5 to 
96.2
79.5 to 
96.9
83.4 to 
94.9
ESX-1 secretion-
Associated protein
Polymorphic sites are denoted by names of genes and pairs of amino acid substitutions from the most common allele to 
one or several alternative allelic states.
Deletions are marked by asterisks (*).Values X
min
 to X
max
 in cells represent confidence ranges estimated for p-value ≤0.05 
(Eq. (1)).
Table 2. Attributable risk of acquisition of DR mutations in sub-populations of Mtb with secondary mutations.
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ranges of attributable risks A → a
|b
 and B → b
|a
do not overlap and A → a
|b
 > B → b
|a
 as in Figure 
2-1. In total, 554 secondary polymorphisms were found, which increase likelihood of acquisi-
tion of 9 out of 10 studied DR mutations. The mutation KasA G269S, rendering resistance to 
INH [41], was strongly associated only with the GidB L16R mutation rendering SM resistance 
[42], which indicates that the former polymorphism is most likely a secondary mutation in 
multidrug resistant Mtb.
A selection of secondary mutations predetermining acquisition of nine of the most widely dis-
tributed DR mutations rendering resistance to FLQ, INH, EMB, SM and para-aminosalisylic acid 
(PAS) in multidrug resistant Mtb are shown in Table 2. Values X
min
 to X
max
 in Table 2 represent 
confidence ranges estimated for p-value ≤ 0.05 (Eq. (1)). It was found that the acquisition of DR 
mutations require allelic alterations in many other proteins including several transmembrane 
transporter and efflux proteins, osmoprotectant, transcriptional regulators and some other pro-
teins. Strong cross-associations between DR polymorphisms characteristic for different lineages 
(Figure 1) favors the hypothesis of strong functional associations between these mutations com-
pared to neutral genetic drift. The identified proteins predefining the acquisition of the DR pheno-
type may be molecular targets for development of new drugs for antibiotic resistance reversion.
5. The concept of the drug resistance reversion and implementation 
thereof
The concept of drug resistance reversion was applied in recent studies [7, 41]. Drug resistance 
mutations are often incompatible with one another, as shown by negative linkage disequilibrium 
values. This suggests that the cumulative fitness cost of mutations is often too high for the result-
ing strain to be viable. FS-1 is a new drug which seems to exploit this tendency. Active units of 
FS-1 are aggregated micelles containing complexes of tri-iodide molecules coordinated by metal 
ions and integrated into a dextrin-polypeptide moiety. The basic formula of the micelle is:
  [ { ( L n   ( MeJ 3 ) + ) y   [Me ( L m ) J] + x }   ( Cl − ) y+x+k ] 
where L—dextrin-polypeptide ligand; Me—Li/Mg ions; n, m, x, y and k—variable integers 
≥1; molecular mass of the micelles is in the range of 30–300 kD. This molecular complex was 
designed to prolong the residence time of moderately oxidative iodine molecules in an organ-
ism and facilitate their transportation to inner tissues.
Studies of XDR-TB infection in animal models showed the reversion of Mtb pathogens to a more 
drug sensitive phenotype after treatment with FS-1 despite the remaining DR related mutations 
in their genomes [7]. Drug resistance reversion was also confirmed on an in vitro model with a 
XDR-TB clinical isolate SCAID 187.0 when cultivated for 60 days in six passages on a medium 
with a sub-lethal dose of ¼ MIC of FS-1. Reduction of the antibiotic resistance of XDR-TB isolates 
obtained during the clinical trial of FS-1 was consistent with the results of the above-mentioned 
laboratory experiments. It was concluded that the DR phenotype requires multiple genes to be 
in specific activity states controlled either by transcription regulation or resulting from specific 
mutations. A combination of genetic variants creates a genomic context of drug resistance.
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Clinical trials of FS-1 has been undertaken in Kazakhstan and registered in the Clinical Trial 
database (www.ClinicalTrials.gov) under an accession number NCT02607449. It was found 
that FS-1 had a high absorption rate after per-oral administration, which was not affected by 
food intake. Peak plasma concentration of FS-1 was observed within 1–2 h after administra-
tion. Gastric juice activated the infusion of FS-1 in stomach. Pharmacokinetic study of FS-1 
showed a long residence time of the drug in the blood stream and an elevated accumulation 
in the liver. The drug was excreted from the test organism mainly by the kidneys.
The preclinical trial of FS-1 included pharmacological studies (primary and secondary phar-
macokinetics); general toxicity determination; tests for mutagenesis, inhibition of reproduc-
tive performance, immune toxicity, mucous membrane irritation and several other general 
physicochemical studies of the compound. FS-1 caused no irritation of the stomach mucosa 
when applied in concentrations of up to 5.0 mg/kg. No ulcerogenic, allergenic, immune 
toxic, mutagenic or carcinogenic side effects were observed after repeated administration of 
FS-1. Also, no cytotoxicity or embryonic toxicity was observed. Toxicological studies attrib-
uted FS-1 to low toxicity compounds with a reduced accumulation in an organism (drug 
accumulation coefficient was 1.85). The maximum endurable dose of FS-1 identified in rats 
was 496 mg/kg, and in mice, 993 mg/kg. The average lethal dose (LD50) in rats was found to 
be 992 mg/kg for both male and female individuals. Therapeutic doses of FS-1 in clinical tri-
als on humans for the treatment of patients with lung XDR-TB infection ranged from 1.0 to 
5.0 mg/kg. During the clinical trials, FS-1 was administrated for up to 6 months in combina-
tion with the antibiotics commonly prescribed for XDR-TB treatment. Currently, in the third 
stage of the clinical trials, FS-1 is administrated at a concentration of 2.5 mg/ml for 6 months. 
Clinical studies complied with the regulations and recommendations of the Ministry of 
Health of Kazakhstan and were approved by the respective committees of the Ministry.
The first phase of clinical trials was undertaken in 2009–2010 at the Central Clinical Hospital 
of the Executive Officer of the President of Kazakhstan. During this phase, the drug tolerance 
and safety of a unitary and repeated per-oral intake of the drug by healthy volunteers were 
determined. Hematological parameters, including measuring the concentrations of impor-
tant microelements, i.e., potassium, sodium, magnesium and calcium; functions of liver and 
kidney, electro-physiological parameters of myocardium, metabolism of proteins, hydrocar-
bons and lipids, were monitored. Biochemical parameters of the blood plasma of volunteers 
remained normal during the study. It was found that the administration of FS-1 activated 
cellular immunity and synthesis of γ-interferon.
The second phase of clinical trials was conducted in 2010–2012 at the Municipal anti-tuber-
culosis clinic in Almaty, at the National Centre of Tuberculosis in Almaty and at the Regional 
anti-tuberculosis clinic of the Karaganda region in Kazakhstan. In total, 220 volunteer patients 
with active XDR-TB lung tuberculosis were involved in this phase of trials. The volunteers 
ranged from 18 to 65 years old, with a body mass within 10% of the average body weight of 
male and female adults, with no contraindications to the common MDR-TB antibiotic therapy. 
Informed consent principles, which imply voluntariness of participation and understanding 
of the matter of the trial, were complied with. Contraindications to participation in the trial 
were: pregnancy; oncological diseases; HIV; 3-fold higher than normal ALT/AST or increased 
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creatinine in blood; dermatomycosis; mental disorders; hypothyroidism; any allergies, espe-
cially an allergy to iodine-containing preparations; and any other cardiovascular, kidney or 
liver decompensated concomitant diseases.
The therapeutic efficacy of the drug was evaluated by bacteriological examination of sputum 
samples of patients on Lowenstein-Jensen medium for the presence of Mtb isolates. Other 
tests performed during the trial were: microscopic examination of sputum smears; control-
ling the positive dynamics of recovery by regular X-ray examinations and by general clini-
cal tests; positive body weight dynamics; and the efficacy of prevention of disease relapses. 
The efficacy and safety of the regimen of per-oral administration of FS-1 in concentrations 
of 2.0–5.0 mg/kg during the 6 months in combination with commonly prescribed antibiotics 
against XDR-TB were confirmed in the second phase of the trial. No serious side effects of the 
treatment were recorded. In particular, thyroid gland function was monitored for adverse 
effects. No statistically reliable alterations in the concentration of thyroid hormones in blood 
were observed, which indicated no deleterious effect of this iodine-containing drug on thy-
roid gland functions. The time of complete recovery from XDR-TB was reduced, with no 
disease relapses during the 12 months surveillance, resulting in a significant reduction of the 
average cost of XDR-TB treatment (Table 3).
Mtb isolates were collected on a regular basis during the second phase of the FS-1 clinical tri-
als. It was found that the percentage of drug resistant isolates decreased continuously during 
the treatment course with FS-1 despite the administration of the antibiotics. It was hypoth-
esized that the therapeutic activity of FS-1 may be associated with the reversion of antibiotic 
resistance [37]. This hypothesis was then confirmed in an in vivo experiment on guinea pigs, 
which has been recently published [7].
The third phase of clinical trials began in 2014 and is still in progress. The drug FS-1 has been 
approved as an antibacterial medicine for per-oral administration in a complex of commonly 
prescribed anti-tuberculosis drugs for the treatment of XDR-TB in Kazakhstan (approval cer-
tificate РК-ЛС-5№021305 from 08-04-2015).
XDR TB treatment expenses Conventional antibiotic therapy Combined therapy by 
antibiotics with FS-1
Time of 100% sanation from M. tuberculosis 
isolation from sputum
12–24 months 3–6 months
Percentage of relapses in 12 month surveillance 
period
46.1% Not observed
Daily therapy cost in clinics of Kazakhstan $ 11.7 $ 12.5
Full cost of the treatment course including the 
treatment of disease relapses
$ 4274 or up to $ 8548 in the case of 
TB relapses
$ 2256 (no TB relapses were 
recorded)
Table 3. Summarized efficacy of application of FS-1 in the second phase of the clinical trial in terms of reduction of the 
treatment course duration and cost.
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6. Conclusion
The idea that the DR phenotype is determined by multiple genes was supported in a review 
by Trauner et al. and Müller et al. [9, 13]. They argued that the genetic background of Mtb 
is important in determining the phenotypic effect of DR mutations. Epistasis—the genetic 
interactions that determine a phenotype—and bacterial fitness are the two factors that deter-
mine the evolution of drug resistance. It is thus important to study genes that are directly 
involved in drug metabolism as well as genes that could play a compensatory role, such as 
those involved in aspects of cell physiology, e.g., permeability of the cell. The complexity of 
the genetic and epistatic determination of the DR phenotype allows the development of new 
drugs to induce reversion of drug resistance in populations of pathogens. The phenomenon 
of DR reversion was defined in a review by Baym et al. as an active drug-induced counter-
selection of resistant variants from populations of pathogens [37]. Several theoretical assump-
tions were discussed in this paper to explain the resistance reversion despite the presence of 
selective antibiotics in a medium. Practical application of the antibiotic resistance reversion 
approach to combat multidrug resistant tuberculosis was exemplified in this work by an over-
view of the clinical trial of the new drug FS-1.
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